Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

NCT05332925 · clinicaltrials.gov ↗

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
NSCLC
NSCLC Stage IV

Interventions

DRUG: Standard of care immune checkpoint inhbitors

Sponsor

Jun Zhang, MD, PhD

Collaborators

[object Object]